Structure Therapeutics Inc.

NasdaqGM:GPCR Stock Report

Market Cap: US$1.5b

Structure Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Structure Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-52.7%

Buyback Yield

Total Shareholder Yield-52.7%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Structure Therapeutics: Competitive Data Is Emerging

Jan 03

Companies Like Structure Therapeutics (NASDAQ:GPCR) Are In A Position To Invest In Growth

Nov 25
Companies Like Structure Therapeutics (NASDAQ:GPCR) Are In A Position To Invest In Growth

Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients

Oct 22

We're Hopeful That Structure Therapeutics (NASDAQ:GPCR) Will Use Its Cash Wisely

Aug 11
We're Hopeful That Structure Therapeutics (NASDAQ:GPCR) Will Use Its Cash Wisely

Structure Therapeutics: Yet Another Potential GLP-1 Entrant

Jun 14

Structure Therapeutics' Slim Obesity Hopes In A Pill Take Shape

Jun 05

Here's Why We're Not Too Worried About Structure Therapeutics' (NASDAQ:GPCR) Cash Burn Situation

Mar 10
Here's Why We're Not Too Worried About Structure Therapeutics' (NASDAQ:GPCR) Cash Burn Situation

Structure Therapeutics (NASDAQ:GPCR) Is In A Good Position To Deliver On Growth Plans

Jun 29
Structure Therapeutics (NASDAQ:GPCR) Is In A Good Position To Deliver On Growth Plans

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if GPCR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GPCR's dividend payments have been increasing.

Dividend Yield vs Market

Structure Therapeutics Dividend Yield vs Market
How does GPCR dividend yield compare to the market?
SegmentDividend Yield
Company (GPCR)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.4%
Industry Average (Pharmaceuticals)2.6%
Analyst forecast (GPCR) (up to 3 years)n/a

Notable Dividend: Unable to evaluate GPCR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GPCR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate GPCR's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as GPCR has not reported any payouts.

Discover strong dividend paying companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/21 00:54
End of Day Share Price 2025/01/21 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Structure Therapeutics Inc. is covered by 15 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Evan SeigermanBMO Capital Markets Equity Research
Prakhar AgrawalCantor Fitzgerald & Co.
Zhuhong ChenChina Merchants Securities (HK) Co., Ltd